Notably, tetrabenazine is the only FDA-approved drug for the management of chorea associated with Huntington’s disease [3,4], a condition that helps manage the depletion of dopamine through reversible inhibition of the human vesicular monoamine transporter 2 (VMAT2) [5]. Here, SLC18A2 is linked to juvenile Huntington disease.